Article
Overexpression of canonical prefoldin associates with the risk of mortality and metastasis in non-small cell lung cancer
Author/s | Peñate Salas, Xenia
Praena Fernández, Juan Manuel Romero Pareja, Pedro Enguix Riego, María del Valle Payán Bravo, Laura Vieites Pérez-Quintela, Begoña Chávez de Diego, Sebastián López Guerra, José Luis |
Department | Universidad de Sevilla. Departamento de Enfermería Universidad de Sevilla. Departamento de Genética |
Publication Date | 2020-04-24 |
Deposit Date | 2020-06-26 |
Published in |
|
Abstract | Canonical prefoldin is a protein cochaperone composed of six di erent subunits (PFDN1
to 6). PFDN1 overexpression promotes epithelial–mesenchymal transition (EMT) and increases the growth of xenograft lung cancer (LC) ... Canonical prefoldin is a protein cochaperone composed of six di erent subunits (PFDN1 to 6). PFDN1 overexpression promotes epithelial–mesenchymal transition (EMT) and increases the growth of xenograft lung cancer (LC) cell lines. We investigated whether this putative involvement of canonical PFDN in LC translates into the clinic. First, the mRNA expression of 518 non-small cell LC (NSCLC) cases from The Cancer Genome Atlas (TCGA) database was evaluated. Patients with PFDN1 overexpression had lower overall survival (OS; 45 vs. 86 months; p = 0.034). We then assessed the impact of PFDN expression on outcome in 58 NSCLC patients with available tumor tissue samples. PFDN1, 3, and 5 overexpression were found in 38% (n = 22), 53% (n = 31), and 41% (n = 24) of tumor samples. PFDN1, 3, and 5 overexpression were significantly associated with lower OS, lower disease-free survival (DFS), and lower distant metastasis-free survival (DMFS) for PFDN1 and 3 with a trend for PFDN5. In multivariate analysis, PFDN5 retained significance for OS (hazard ratio (HR) 2.56; p = 0.007) and PFDN1 for DFS (HR 2.53; p = 0.010) and marginally for DMFS (HR 2.32; p = 0.053). Our results indicate that protein response markers, such as PFDN1, 3, and 5, may complement mRNA signatures and be useful for determining the most appropriate therapy for NSCLC patients. |
Citation | Peñate Salas, X., Praena Fernández, J.M., Romero Pareja, P., Enguix Riego, M.d.V., Payán Bravo, L., Vieites Pérez-Quintela, B. y López Guerra, o.L. (2020). Overexpression of canonical prefoldin associates with the risk of mortality and metastasis in non-small cell lung cancer. Cancers, 12 (1052), 1-9. |
Files | Size | Format | View | Description |
---|---|---|---|---|
Overexpression_of_Canonical_Pr ... | 822.5Kb | [PDF] | View/ | |